Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-17
2007-07-17
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S391000, C549S392000
Reexamination Certificate
active
10152152
ABSTRACT:
Psorospermin is a cytotoxic dihydroflranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin analogs to inhibit cellular proliferation.
REFERENCES:
patent: 6933396 (2005-08-01), Whitten et al.
patent: 0 175 376 (1986-03-01), None
Lin et al, Chemical Abstracts vol. 125 No. 392826, “Xanthone derivatives as potential anti-cancer drugs”, 1996.
Kwok et al, Proc. Natl. Sci. USA vol. 95 pp. 13531-13536 “Topisomerase II mediated site-directed alkylation . . . ” (1998).
Abou-Shoer et al , Phytochemistry vol. 27 No. 9 pp. 2795-2800 “Antitumor and cytotoxic . . . ”(1988).
Pachuta et al Jol. Nat. Prod. vol. 49 No. 3 pp. 412-423“Antineoplastic agents from higher . . . ” (1986).
Gonda et al., “Studies on the constituents Anaxagorea luzonesis A. Gray,”Chemical&Pharmaceutical Bulletin, 48:1219-1222, 2000.
Habib et al., “Structure and stereochemistry of psorospermin and related cytotoxic dihydrofuranoxanthones from psorospermun febrifugum,”Journal of Organic Chemistry, 52:412-418, 1987.
Hano et al., “Constituents of the root bark of morus insignis bur. 1. Structures of four new isoprenylated xanthones morusignins A, B, C and D,”Heteocycles, 31:1345-1350, 1990.
Hano et al., “Constituents of the root bark of morus insignis bur. 3. Structures of three new isoprenylated xanthones morusignins I, J and K and an isoprenylated flavone morusignin L,”Heterocycles, 36:1359-1366, 1993.
Jacobs et al., “BMI-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF,” (1999).
Morel et al., “New xanothones from calophyllum caledonicum,”J. Nat. Prod., 63:1471-1474. (2000).
Patel et al., “Studies in synthesis of xanothone derivatives. Part VI—Synthesis of furango- & difurano-xanothones,”Indian Journ. Chem., 26:1035-1038, 1987.
Fellows Ingrid
Hurley Laurence
Schwaebe Michael Kenric
Whitten Jeffrey Paul
Board of Regents , The University of Texas System
Covington Raymond
Cylene Pharmaceuticals, Inc.
Fulbright & Jaworski LLP
McKenzie Thomas
LandOfFree
Methods for preparation and use of psorospermin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preparation and use of psorospermin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preparation and use of psorospermin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805012